title: Considerations for controlling invasive meningococcal disease in high income countries.
abstract: The development of conjugate vaccines has enabled the prevention and control of Neisseria meningitidis caused by serogroups A, C, W-135 and Y. Vaccines that provide protection against a broad number of serogroup B strains likely will be available soon to enable greater control of meningococcal disease in high income countries. We present an argument for adequate post-marketing surveillance to monitor epidemiological shifts and to provide a context for the safety and reactogenicity of serogroup B vaccines, including the newer recombinant vaccines. We also offer a series of recommendations to address possible concerns about vaccine safety.
authors.affiliation: Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway.
authors.forename: Johan
authors.initials: J
authors.lastname: Holst
authors.forename: Hanne
authors.initials: H
authors.lastname: Nøkleby
authors.forename: Julie A
authors.initials: JA
authors.lastname: Bettinger
mesh_terms: D019049:Developed Countries; D006801:Humans; D016920:Meningitis, Bacterial / Q000453:epidemiology / Q000517:prevention & control; D008589:Meningococcal Infections / Q000453:epidemiology* / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D009345:Neisseria meningitidis / Q000145:classification / Q000276:immunology / Q000302:isolation & purification*; D011358:Product Surveillance, Postmarketing / Q000379:methods; D018571:Sentinel Surveillance; D018805:Sepsis / Q000453:epidemiology / Q000517:prevention & control
chemical_list: D022401:Meningococcal Vaccines